Poster Spotlight 7: Early Triple Negative Breast Cancer—Biomarkers and Novel Approaches 

Moderator

Hope S. Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA

Presentation numberPD7-01

Circulating determinants of response to immunotherapy in triple negative breast cancer (TNBC)

Nickolas Stabellini, Case Western Reserve University, Cleveland, OH

Presentation numberPD7-02

Transcriptomic profiling of the tumor microenvironment indicates differential response to neoadjuvant chemotherapy with and without pembrolizumab in early TNBC

Ana C Garrido-Castro, Dana-Farber Cancer Institute, Boston, MA

Presentation numberPD7-03

Circulating Immune Correlates of Pathological Response to Neoadjuvant Pembrolizumab plus Chemotherapy in High-Risk, Early-Stage Triple-Negative Breast Cancer

Clinton Yam, The University of Texas MD Anderson Cancer Center, Houston, TX

Presentation numberPD7-04

Transcriptomic Profiling Reveals PMSB8-AS1 and LINC00996 as Potential Prognostic Biomarkers in Triple-Negative Breast Cancer Treated with Neoadjuvant Docetaxel-Carboplatin

Sara López-Tarruella, Hospital General Universitario Gregorio Marañón. IiSGM. Universidad Complutense, Madrid, Spain

Presentation numberPD7-05

Gut Microbiota Signatures are Associated with Response in Triple Negative Breast Cancer Patients Treated with Standard Neoadjuvant Chemotherapy

Rena Feinman, Hackensack Meridian Health, Nutley, NJ

Presentation numberPD7-06

Discussant: Novel biomarkers to predict response

Evanthia T Roussos Torres, University of Southern California, Los Angeles, CA

Presentation numberPD7-07

Three-year event-free survival from a phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative early stage/resectable breast cancer (ipilimumab/nivolumab cohort)

Heather L McArthur, UTSW, Dallas, TX

Presentation numberPD7-08

Exploratory phase II trial of camrelizumab (an anti-PD-1 antibody) combined with apatinib (a VEGFR-2 inhibitor) and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis

Ting Luo, West China Hospital, Sichuan University, China, Chengdu, China

Presentation numberPD7-09

Feasibility of a machine learning-based peripheral blood immunoprofiling platform to stratify patients with early-stage triple-negative breast cancer (eTNBC) by neoadjuvant therapy response

Chiara Corti, Dana-Farber Cancer Institute, Boston, MA

Presentation numberPD7-10

Neo-n (neon): three-year event-free survival and ultrasensitive ctdna dynamics in early triple-negative breast cancer (tnbc) treated with neoadjuvant carboplatin/paclitaxel and nivolumab

Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

Presentation numberPD7-11

Impact of neoadjuvant pembrolizumab on ovarian function in young patients with triple-negative breast cancer (TNBC): Longitudinal analysis from NeoSTOP and NeoPACT trials

Priyanka Sharma, University of Kansas Medical Center, Kansas City, KS

Presentation numberPD7-12

Discussant: Novel approaches and biomarker driven treatment

Rebecca Dent, National University Hospital Singapore, Singapore, Singapore